Literature DB >> 30506150

Patterns of failures after surgical resection in olfactory neuroblastoma.

Nalee Kim1, Chang Geol Lee1, Eui Hyun Kim2, Chang-Hoon Kim3, Ki Chang Keum1, Kyu-Sung Lee2, Jong Hee Chang4, Chang-Ok Suh5,6.   

Abstract

INTRODUCTION: Patterns of failure in patients with olfactory neuroblastoma (ONB) according to two surgical approaches, craniofacial resection (CFR) and endoscopic surgery (ENDO), have yet to be analyzed.
METHODS: We retrospectively reviewed 28 patients with surgically treated ONB between January 1995 and October 2017. Fourteen (50.0%) patients underwent CFR (9 CFR alone, 5 ENDO-assisted CFR) and 14 (50.0%) underwent ENDO. Nineteen (67.9%) patients underwent post-operative radiotherapy (RT).
RESULTS: At a median follow-up of 53.8 months (range 10.4-195.3), the 5-year progression-free survival (PFS) and 10-year overall survival were 37.3% and 57.5%, respectively. Patients with adjuvant RT had a 5-year PFS of 46.7%, whereas those treated with surgery alone had a 5-year PFS of 19.4% (p = 0.01). Locoregional failure (LRF) occurred in ten patients (median 59.6 months after initial diagnosis; range 12.7-59.7). Neck node metastasis occurred in 25.0% (7 of 28). Five patients with ENDO showed LRF and underwent proper subsequent treatments with either surgery or adjuvant RT. Approximately 35.7% patients (five patients) in the CFR group experienced distant metastasis in the intracranial dura region (median 116.4 months after initial diagnosis; range 2.6-142.4). Three of four patients who developed LRF after CFR developed dura-based metastasis.
CONCLUSIONS: Both dura-based and neck node metastasis in the delayed phase were distinct patterns of failure in ONB. Patterns of recurrence differed based on surgical approach; dura-based metastases were common after CFR. LRF was the distinct failure pattern in ENDO, but could be successfully salvaged. Treatment outcome was improved considerably with RT following surgical resection.

Entities:  

Keywords:  Craniofacial resection; Endoscopy; Head and neck cancer; Olfactory neuroblastoma; Survival

Mesh:

Year:  2018        PMID: 30506150     DOI: 10.1007/s11060-018-03056-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol.

Authors:  Joanne Rimmer; Valerie J Lund; Timothy Beale; William I Wei; David Howard
Journal:  Laryngoscope       Date:  2014-02-04       Impact factor: 3.325

2.  Cancer of the nasal cavity and paranasal sinuses: a series of 115 patients.

Authors:  V Svane-Knudsen; K E Jørgensen; O Hansen; A Lindgren; P Marker
Journal:  Rhinology       Date:  1998-03       Impact factor: 3.681

Review 3.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

4.  Esthesioneuroblastoma: is there a need for elective neck treatment?

Authors:  Candan Demiroz; Orit Gutfeld; Mohamed Aboziada; Doris Brown; Lawrence J Marentette; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-15       Impact factor: 7.038

5.  Radiotherapy for esthesioneuroblastoma: is elective nodal irradiation warranted in the multimodality treatment approach?

Authors:  O Kyu Noh; Sang-wook Lee; Sang Min Yoon; Sung Bae Kim; Sang Yoon Kim; Chang Jin Kim; Kyung Ja Jo; Eun Kyung Choi; Si Yeol Song; Jong Hoon Kim; Seung Do Ahn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-24       Impact factor: 7.038

6.  Patterns of regional and distant metastasis in esthesioneuroblastoma.

Authors:  Victoria E Banuchi; Laura Dooley; Nancy Y Lee; David G Pfister; Sean McBride; Nadeem Riaz; Mark H Bilsky; Ian Ganly; Jatin P Shah; Dennis H Kraus; Luc G T Morris
Journal:  Laryngoscope       Date:  2016-02-10       Impact factor: 3.325

7.  Esthesioneuroblastoma: the Johns Hopkins experience.

Authors:  V A Resto; D W Eisele; A Forastiere; M Zahurak; D J Lee; W H Westra
Journal:  Head Neck       Date:  2000-09       Impact factor: 3.147

8.  Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients.

Authors:  Anand K Devaiah; Michael T Andreoli
Journal:  Laryngoscope       Date:  2009-07       Impact factor: 3.325

9.  Esthesioneuroblastoma: the Northwestern University experience.

Authors:  Athanassios Argiris; Jose Dutra; Paraskevi Tseke; Kenneth Haines
Journal:  Laryngoscope       Date:  2003-01       Impact factor: 3.325

10.  Optimization of long-term outcomes for patients with esthesioneuroblastoma.

Authors:  Thomas J Ow; Ehab Y Hanna; Dianna B Roberts; Nicholas B Levine; Adel K El-Naggar; David I Rosenthal; Franco DeMonte; Michael E Kupferman
Journal:  Head Neck       Date:  2013-06-18       Impact factor: 3.147

View more
  2 in total

1.  Human Olfaction without Apparent Olfactory Bulbs.

Authors:  Tali Weiss; Timna Soroka; Lior Gorodisky; Sagit Shushan; Kobi Snitz; Reut Weissgross; Edna Furman-Haran; Thijs Dhollander; Noam Sobel
Journal:  Neuron       Date:  2019-11-06       Impact factor: 17.173

2.  Intensity-modulated particle beam radiation therapy in the management of olfactory neuroblastoma.

Authors:  Weixu Hu; Jiyi Hu; Jing Gao; Jing Yang; Xianxin Qiu; Lin Kong; Jiade J Lu
Journal:  Ann Transl Med       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.